Research programme: oncology vaccines - Theravectys

Alternative Names: THV 02

Latest Information Update: 20 May 2015

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator THERAVECTYS
Class Cancer vaccines; Dendritic cell vaccines
Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Adult T-cell leukaemia-lymphoma
New Molecular Entity No

Highest Development Phases

Preclinical Adult T-cell leukaemia-lymphoma; Cancer

Most Recent Events

14 Apr 2015 THERAVECTYS and the Curie Institute agree to co-develop oncology vaccines under a long-term R and D alliance
04 Feb 2015 THV 02 receives Orphan Drug status for Adult T-cell leukaemia-lymphoma in European Union
26 Jan 2015 Preclinical trials in Adult T-cell leukaemia-lymphoma in France (Parenteral)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.